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Abstract 
Sulforaphane (SFN) has shown anti-cancer effects in cellular and animal studies but its effectiveness 
has been limited in human studies. Here, the effects of SFN were measured in both human 
hepatocyte (HHL5) and hepatoma (HepG2) cells. Results showed that SFN inhibited cell viability and 
induced DNA strand breaks at high doses (≥ 20 µM). It also activated the nuclear factor (erythroid-
derived 2)-like 2 (Nrf2), and increased intracellular glutathione (GSH) levels at 24 hours. Pre-
treatment with a low dose SFN (≤5 µM) protected against hydrogen peroxide (H2O2)-induced cell 
damage. High doses of SFN were more toxic towards HHL5 compared to HepG2 cells; the difference 
is likely due to the disparity in the responses of Nrf2-driven enzymes and -GSH levels between the 
two cell lines. In addition, HepG2 cells hijacked the cytoprotective effect of SFN over a wider dose 
range (1.25 - 20 µM) compared to HHL5. Manipulation of levels of GSH and Nrf2 in HepG2 cells 
confirmed that both molecules mediate the protective effects of SFN against H2O2. The non-specific 
nature of SFN in the regulation of cell death and survival could present undesirable risks, i.e. be 
more toxic to normal cells, and cause chemo-resistance in tumor cells. These issues should be 
addressed in the context for cancer prevention and treatment before large scale clinical trials are 
undertaken.  
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Introduction 
Isothiocyanates, found in cruciferous vegetables, have been identified as chemopreventive 
phytochemicals. One of the most important dietary isothiocyanates  is sulforaphane (1-
isothiocyanate-(4R)-(methylsulfinyl) butane, SFN), first isolated from broccoli in 1992
1
. SFN is derived 
from glucoraphanin (4-methylsulfinylbutyl glucosinolate), and is abundant in both broccoli and 
broccoli sprouts
2
. The cytoprotective effect of SFN comes largely from the activation of nuclear 
factor (erythroid-derived 2)-like 2 (Nrf2), a master regulator involved in cell redox homeostasis and 
stress adaptation
3
. Under basal conditions, Nrf2 is sequestered in the cytoplasm by redox-sensitive 
Kelch-like ECH-associated protein 1 (Keap1), which associates with Cul3 and brings Nrf2 in close 
proximity to Cul3-based E3 ligase complex so Nrf2 degrades via the ubiquitin-26S proteasomal 
pathway
4
. With a half-life of around 20 minutes
5
, Nrf2 is normally maintained at a low cellular level. 
The interaction of SFN with Keap1 disrupts this function and allows nuclear accumulation of Nrf2. 
Although there are conflicting in vitro and in vivo data regarding which cysteine residues react with 
SFN, evidence showed that modification of C151 is essential for its action
6
. Nrf2 then binds to the 
antioxidant responsive element (ARE) and enhances the transcription of more than 200 target genes, 
many of which provoke strong cytoprotective responses. Of significance is that Nrf2 controls the 
production, utilization and regeneration of glutathione (GSH), the most abundant antioxidant 
cofactor within cells
7
, by regulating the rate-limiting enzyme for GSH synthesis, Glutamate cysteine 
ligase (GCL, previous known as glutamylcysteine synthetase, γ-GCS)
8
, reactive oxygen species (ROS)-
detoxifying enzymes such as glutathione transferase (GST)
9
, and NADPH-generating enzymes
10
. 
In addition to the cytoprotective effect, SFN has also been shown to exhibit cytotoxic effects 
including promoting ER stress and cell death
11–13
; disrupting mitochondria
14
, tubulin and microtubule 
function
15–17
; inducing DNA damage
18
, apoptosis and cell cycle arrest
19–22
; inhibiting telomerase 
activity
11,23
 and protein-protein interaction in Hsp90 complex
24
. The complex bioactivities of SFN and 
subsequent cellular responses are highly dependent upon the dose and duration of SFN treatment. 
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Therefore, understanding of the effects of SFN in non-cancerous and cancerous cells has great 
importance in cancer management. 
An effective cancer therapy requires high selectivity towards cancer cells. Comparisons of 
results of SFN bioactivities on normal and cancerous cells have been inconsistent. Several normal 
epithelial cell lines are relatively resistant to apoptosis induction by SFN at concentrations that are 
lethal to cancer cells
25,26
. Zeng et al reported SFN activated survival signalling in non-tumorigenic 
NCM460 colon cells but activated apoptotic signalling in tumorigenic HCT116 colon cells, and that 
may play a critical role in the higher potential of SFN to inhibit cell proliferation in colon cancer cells 
than in normal colon cells
27
. The transcription factor specificity protein 1 was linked to SFN-induced 
prostate cancer specific cytotoxicity
28
. Conversely, SFN was more cytotoxic to lymphoblastoid than 
to leukaemia cells
29
. The effects of SFN on non-transformed T-lymphocytes were similar to those 
recorded on Jurkat T-leukaemia cells
30
. SFN showed broad and complex effects on DNA methylation 
profiles in both normal and cancerous prostate epithelial cells
31
 and regulated the Nrf2/ARE 
signalling pathway differently in human untransformed epithelial colon cells when compared to 
colorectal cancer cells
32,33
. Negrette-Guzman et al demonstrated SFN modulates mitochondrial 
dynamics differentially in normal and cancer cells
34
. The transcriptional response to SFN on cell cycle 
related genes was dependent on the cell line and presumably the state of cancer progression
35,36
. 
However, to date, an understanding of why SFN has any specificity remains elusive. 
The aim of this study was to compare the cytotoxic and cytoprotective effects of SFN in a 
human hepatoma cell line, HepG2, and in an immortalised human hepatocyte-derived cell line, 
HHL5
37
 , thereby providing evidence on the possible dual role of SFN in cancer biology. 
 
Experimental methods 
Materials 
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SFN was purchased from Toronto Research Chemicals (Canada). 3-(4,5-Dimethyilthiazol-2-yl)-2,5-
diphenyltetrayolium bromide (MTT), dimethyl sulfoxide (DMSO), hydrogen peroxide (H2O2), DL-
Buthionine sulfoximine (BSO), and Bradford reagent were all purchased from Sigma-Aldrich (Dorset, 
UK). Complete protease inhibitors were obtained from Roche Applied Science (West Sussex, UK). 
Primary antibodies to Nrf2, GCS, catalase (CAT), superoxide dismutase-1 (SOD-1), heme oxygenase-1 
(HO-1), NAD(P)H: quinone oxidoreductase (NQO1), glutathione peroxidase 4 (GPX4), Sam68, β-actin, 
HRP-conjugated goat anti-rabbit and rabbit anti-goat IgG were all purchased from Santa Cruz 
Biotechnology (Santa Cruz, Germany). Primary antibody to phospho-Chk2 (Thr68) was purchased 
from Cell Signalling (Hitchin, UK). The siRNAs for Nrf2 (target sequence, 5′-
CCCATTGATGTTTCTGATCTA-3′) and AllStars Negative Control siRNA were purchased from Qiagen 
(West Sussex, UK). Electrophoresis and western blotting supplies were obtained from Bio-Rad 
(Hertfordshire, UK), and the chemiluminescence kit was from GE Healthcare (Little Chalfont, UK). 
 
Cell culture  
Immortalised human hepatocytes, defined as HHL5 and HepG2 cells were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Gibco) containing 4.5 g/L D-glucose and Non-Essential Amino 
Acids, supplemented with 10% heat-inactivated foetal bovine serum (FBS, Invitrogen), 1% L-
glutamine (200 mM, Gibco), antibiotics (penicillin 100 U/ml and streptomycin 100 µg/ml, Gibco) at 
37°C, 5% (v/v) CO2. When the cells achieved 70-80% confluence, they were exposed to various 
concentrations of SFN for different times with DMSO (0.1%) as control. 
 
MTT assay 
Cells were seeded into 96-well plates and allowed to grow to approximately 70-80% confluency. 
After exposure to experimental conditions, MTT (5mg/ml) was added and incubated with the cells at 
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37°C for 1 h. The formazan crystals produced were dissolved in DMSO and the absorbance was 
determined at test wavelength of 570 nm and background wavelength at 670 nm. Cell viability (%) 
was determined as [A570nm-A670nm (test)] / [A570nm-A670nm (control)] × 100%; the half-maximal 
inhibitory concentration (IC50) was calculated with CalcuSyn software Version 2.0 (Biosoft, UK). 
 
Alkaline Comet assay 
Cells were seeded into 24-well plates and allowed to grow to approximately 70-80% confluency, 
then placed in experimental conditions. Cells were then harvested and resuspended in PBS 
containing 10% DMSO.  The alkaline Comet assay procedure was performed as previously 
described
38
. Levels of DNA strand breaks were expressed as tail intensity (% DNA in the Comet tail). 
 
Annexin V/PI apoptosis assay 
HepG2 cells were seeded on 12-well plates at a density of 5×10
4
 cells per well and incubated at 37°C 
for 48 hours. After treatment with 0, 1.25, 2.5, 5, 10, 20 μM SFN for 24 hours, cells were exposed to 
700 μM H2O2 for another 24 hours. Medium and PBS used to wash the cell layer were then collected. 
Cells were trypsinised and added to the collection. After centrifugation at 200 g for 5 min at 4°C, the 
pellets formed were washed with cold PBS before being re-suspended in 1x binding buffer at a 
density of 1x10
5
/mL according to the instructions from the Annexin V-FITC apoptosis detection kit 
(eBiosciences, UK). Samples were run on a flow cytometer (Cube 6, Sysmex Partec, Germany). For 
each sample 10,000 events were collected, and the data were analysed using FlowJo software 
(Treestar Inc., USA).  
 
High-performance liquid chromatography (HPLC) analysis of intracellular GSH 
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Cells were seeded into 6-well plates and allowed to grow to approximately 70-80% confluency, then 
placed in experimental conditions. Cells were then harvested and suspended in 75 μL PBS containing 
5 mM diethylenetriaminepentaacetic acid and 300 μL 50 mM methanesulfonic acid. GSH-containing 
supernatants were extracted from cells and analysed by HPLC as previous described
39
. Briefly, GSH 
was derivatized using monobrow mobimane (mBBr), the GSH-mBBr adduct was then measured by 
high-performance liquid chromatography (HPLC) with fluorescence detection. The separation was 
performed on an ACE-AR C18 reversed phase column (4.6 × 250 mm, 5 µm, HiChrom) with a mobile 
phase containing (0.25% acetic acid and 10% methanol in H2O, pH4) and a flow rate of 1 mL/min. 
Detection was conducted with excitation wavelength at 385 nm and emission wavelength at 460 nm. 
The GSH-mBBr adduct peak eluted at 8.9 min and was quantified from a standard curve. The 
concentration of GSH was expressed as nmol/mg of cellular soluble protein. 
 
Knockdown of Nrf2 by siRNA 
Transfection of siRNA was performed using HiPerFect transfection reagent (Qiagen, West Sussex, UK) 
according to the manufacturer’s protocol. For Comet assay, HepG2 cells were seeded at 0.5 - 1.5 x 
10
5
 cells/well of a 24-well plate in 0.5 ml of complete medium, then 30 nM siRNA and 3 μL of 
HiPerFect transfection reagent were added to 100 μL medium without serum or antibiotics, mixed 
and incubated for 5-10 mins at room temperature to allow the formation of transfection complexes. 
The complexes were then added drop-wise to each well to give a final siRNA concentration of 5 nM. 
Cells were cultured for additional 24 hours. The Comet assay was then performed as described. For 
MTT assay, reverse transfection of adherent cells in 96-well plates was used. The MTT assay was 
performed after 24 hours as described. 
 
Protein extraction and immunoblotting 
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Cells were seeded into 6-well plates for total protein extraction, or 10 cm dishes for the nuclear 
protein extraction. After cells reached 70-80% confluence, they were placed in experimental 
conditions. Cell monolayers were washed twice with ice-cold PBS and lysed with a 6:1 mixture of 
NP40: proteinase inhibitor for whole protein extraction, or with the Nuclear Extract Kit (Active Motif) 
for nuclear protein extraction. Protein concentration was determined by the Bradford assay. 
Protein extracts were loaded onto 10% SDS-polyacrylamide gels. After electrophoresis, proteins 
were transferred to polyvinylidene difluoride (PVDF) membrane, which was then blocked with 5% fat 
free milk in PBST (PBS with 0.01% Tween 20) for 1 h, incubated with primary antibody overnight at 
4◦C and HRP-conjugated secondary antibody for 1 h. Immunoreactivity was determined by a 
chemiluminescence detection kit (GE Healthcare, Amersham, UK) and quantified by ImageJ
40
. 
 
Statistics  
Data were represented as the mean ± SD (standard deviation). A Student’s t-test analysis was 
performed to determine any statistical difference between two groups. One-way ANOVA with 
Tukey’s post hoc analysis was used to estimate associations. A p value <0.05 was considered 
statistically significant. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
Results 
Effect of SFN on cell viability and DNA integrity  
The cytotoxicity of SFN was measured by MTT assay so that the appropriate experimental 
concentrations for further investigation could be established. Both HHL5 and HepG2 cells were 
cultured in 96-well plates to 70 to 80% confluence and then treated with SFN (1.25 to 160 μM) for 24 
hours. Results indicated that SFN (≥20 μM) decreased the metabolic activities of both cell lines in a 
dose-dependent manner (Figure 1A). With increasing SFN doses, a decrease of cell confluence and 
an increase of detached cells and cell debris were observed. The IC50 values of SFN were 30.2 and 
54.9 μM in HHL5 and HepG2 cells respectively, indicating that HHL5 cells were more susceptible to 
cytotoxicity from SFN than the hepatoma HepG2 cells. In addition, 1.25 μM SFN treatment increased 
cell viability in HepG2 cells significantly but not in HHL5 (p <0.05). 
The genotoxicity of SFN was measured in both cell lines by the Comet assay, using doses of 
1.25 to 20 µM to avoid over-cytotoxicity. Baseline DNA damage (without addition of SFN) in HHL5 
and in HepG2 was 7.58 vs 15.94% respectively, represented as background tail intensity (Figure 1B). 
The difference may be as a result of the genomic instability of the cancer cells compared to the 
normal cells
41
. After 24 hours, there was a significant increase in DNA damage from 20 μM SFN 
treatment in both cell lines, 21.15 and 24.57% in HHL5 and HepG2 respectively; a 2.8-fold increase in 
DNA damage in HHL5 and 1.5-fold in HepG2 compared to controls. Furthermore, 1.25 to 10 µM SFN 
decreased DNA damage in HepG2 cells but not in HHL5 cells. 
To reduce the chances of DNA repair processes completely repairing any damage from 
genotoxic insults, the Comet assay was performed after 30 mins exposure to 20, 40, 80 μM SFN 
treatment in both cell lines (Figure 1C). Results showed SFN caused DNA damage in a dose-
dependent manner in both cell lines, with a 2.8-fold increase at 80 μM SFN treatment in HHL5 and 
1.8-fold in HepG2 compared to their corresponding controls. These data are consistent with the 
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cytotoxicity observed between HHL5 and HepG2 cells, suggesting that SFN is more toxic to HHL5 
than to HepG2 cells. 
 
Figure 1. Effect of SFN on cell viability and genotoxicity in HHL5 and HepG2 cells. (A) Cells were 
treated with different doses of SFN with DMSO (0.1%) as control for 24 hours, then cell viability was 
determined by MTT assay. Results represent the mean ± SD (n ≥ 5). Lines above the data points 
indicates significant differences from their corresponding control group. (B) Cells were treated with 
different doses of SFN with DMSO (0.1%) as control for either 24 hours or 30 mins (C), then DNA 
damage was determined by the alkaline Comet assay. Results represent the mean ± SD (n ≥ 3). 
Statistical significance from the control, *p <0.05, **p <0.01. 
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Protective effect of SFN against H2O2-induced cell injury 
The protective effect of SFN against H2O2-induced cell death in both cell lines was determined by 
MTT assay (Figure 2A). Cells were pre-treated with SFN (1.25 to 20 µM) for 24 hours then treated 
with H2O2 for another 24 hours. The dose of H2O2 treatment was at the IC50 value in each cell line, i.e. 
400 µM and 700 µM in HHL5 and HepG2 respectively (Supplementary Figure 1A). For HHL5 cells, pre-
treatment with 1.25 to 5 µM SFN alleviated cell death induced by H2O2, though pre-treatment with 
10 and 20 µM SFN led to more cell death compared to H2O2 treatment alone (pre-treated with 0.1% 
DMSO as control). However, in HepG2 cells, a protective effect was observed from 1.25 to 20 µM 
SFN pre-treatments in the MTT assays, which was further confirmed using Annexin V/PI double 
staining. H2O2 treatment alone caused significant apoptotic cell death: 5.63% necrotic cells (PI 
positive) and 30.23% apoptotic cells (Annexin V positive). Pre-treatment with SFN (1.25 to 20 µM) 
significantly reduced the cytotoxicity induced by H2O2 with an observable increase in the viable cell 
percentage (double negative) relative to the non-pre-treated cells (Figure 2B). 
The degree by which SFN could protect against H2O2-induced DNA damage was then tested 
by Comet assay (Figure 2C). Cells were pre-treated with SFN (2.5, 5, 10 µM) for 24 hours followed by 
60 µM H2O2 treatment for 30 mins. The dose of H2O2 was determined as shown in Supplementary 
Figure 1B. In HHL5 cells, only SFN 5 µM pre-treatment provided significant protection against H2O2-
induced DNA damage; while in HepG2, there was a dose-dependent protective effect from all 
concentrations of SFN pre-treatment. This result agreed with the changes in p-Chk2 (Thr68) at the 
protein level observed from Western blotting (Figure 2D). The phosphorylation of checkpoint kinase 
2 (Chk2) indicates its activation, which is well documented as a marker of cellular response to DNA 
damage
42
. H2O2 markedly increased the level of p-Chk2 whereas with SFN pre-treatment, p-Chk2 
protein decreased in a dose-dependent manner in HepG2 but not in HHL5. These results indicate 
that SFN significantly reduced the DNA damage caused by H2O2 in HepG2 but not in HHL5 cells. 
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Figure 2. Protective effect of SFN against H2O2-induced cell injury. (A) Cells were pre-treated with 
different doses of SFN for 24 hours and then incubated with H2O2 (60 µM) for another 24 hours. Cell 
viability was measured by MTT assay. Results represent the mean ± SD (n ≥ 5). Statistical significance 
from H2O2 control, *p <0.05, **p <0.01. (B) HepG2 cells were pre-treated with SFN for 24 hours 
before exposure to H2O2 (700 µM) for 24 hours, followed by Annexin V/PI staining detected by a flow 
cytometer. Results represent apoptotic and necrotic cells percentage as mean ± SD (n = 3). (C) Cells 
were pre-treated with different doses of SFN for 24 hours and then incubated with H2O2 (60 µM) for 
another 30 mins. DNA damage was measured by Comet assay. Tail intensity were measured for at 
least 100 Comets per sample. Statistical significance from H2O2 control, *p <0.05, **p <0.01. (D) The 
protein level of p-Chk2 in whole cell lysates was detected by Western blot and normalized against β–
actin. 
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Effect of SFN on intracellular GSH levels and Nrf2 pathway 
The intracellular GSH levels in HHL5 and HepG2 cells were determined by HPLC assay. The basal level 
of intracellular GSH was 43.9 ± 6.1 nmol/mg in HHL-5 and 60.7 ± 8.5 nmol/mg protein in HepG2 
(Supplementary Figure 2). SFN treatment for 24 hours, increased the levels of GSH in a dose 
dependent manner in both cell lines (Figure 3A). However, there was a drop of GSH level after 20 
µM SFN treatment in HHL5 but not in HepG2 cells, which may represent a toxic effect.  
Time courses of the GSH levels in both cell lines were performed following 10 µM SFN 
treatments (Figure 3B). Results indicated that SFN caused a biphasic depletion and restoration of 
GSH in both cell lines. The depletion occurred in HHL5 cells at 3 and 6 hours after SFN exposure, 
where the GSH level decreased to 60 and 72% of control levels respectively. In HepG2 cells, GSH 
level decreased to 51% at 3 hours of SFN treatment but was restored to control levels at 6 hours. At 
24 hours, the GSH levels were increased around 2-fold of controls in both cell lines. These results 
were in accordance with those of Kim and coworkers
43
 who showed early down regulation of GSH 
between 0 and 4 hours and up regulation between 4 and 24 hours in HepG2-C8 cells. 
Since Nrf2 translocation to the nucleus is one of the key events required in the regulation of 
the Nrf2-Keap1-ARE signalling pathway, it is important to determine the time- and dose- response of 
SFN on this translocation. Here the time and dose courses of activation Nrf2 by SFN were tested in 
both cell lines. Untreated HHL5 and HepG2 cells had low Nrf2 levels in the nucleus consistent with 
the continuous degradation of Nrf2 under homeostasis. Upon SFN treatment, a prompt increase of 
Nrf2 appeared after 1 hour in both cell lines (Figure 3), suggesting the liberation of Nrf2 from Keap1 
suppression and subsequent Nrf2 nuclear translocation. The nuclear accumulation of Nrf2 plateaued 
after 2 hours and remained steady for 24 hours. The dose response from 4 hours SFN treatment in 
HHL5 cells is in agreement with previous studies
44
. In HepG2, SFN at 2.5 to 20 µM also induced 
significant and dose-dependent translocation of Nrf2 into the nucleus. Comparing the basal levels of 
nuclear Nrf2 in these two cell lines, HepG2 showed a 3.3-fold higher basal level than HHL5. 
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Moreover, SFN at 5 µM (4 h) induced 2.9- and 6.2-fold increase of Nrf2 protein level in HHL5 and 
HepG2 cells respectively. As shown in Figure 3F, GCS was 9.8-fold higher in HepG2 cells than that in 
HHL5 cells, which was consistent with the basal level of GSH being higher in HepG2 cells compared 
to HHL5 cells. Other Nrf2-driven enzymes such as CAT, SOD1 and NQO1 were all found significantly 
higher in HepG2 cells than that of HHL5 cells, and that may explain the stronger ROS scavenging 
capability of HepG2 cells we observed in Supplementary Figure 1A. 
 
 
 
Figure 3. Effect of SFN on intracellular GSH levels and Nrf2 activation in HHL5 and HepG2 cells. (A) 
Cells were treated with different doses of SFN with DMSO (0.1%) as control for 24 hours, or (B) cells 
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were treated with 10 µM SFN for 0, 3, 6, 12, 24 hours. The intracellular GSH level was measured by 
HPLC. Results represent the mean ± SD (n=3). Statistical significance from control, *p <0.05, **p 
<0.01. Nuclear protein was extracted from cells treated with (C) 10 µM SFN from 0 to 24 hours, (D) 
SFN from 0 to 20 µM for 4 hours, or (E) SFN 5 µM or DMSO (0.1%) for 4 hours, and Nrf2 was 
detected by Western blotting. RNA-binding protein SAM was used as a loading control. (F) The whole 
protein levels of GCS, CAT, SOD1, NQO1, SOD and GPX4 were detected by Western blotting using 
both cell lines. Β-Actin was used as a loading control.   
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The role of Nrf2 and GSH in cytotoxic and cytoprotective effects of SFN 
Since higher basal levels of Nrf2 and GSH were observed in HepG2 cells compared to those in HHL5 
cells, their role in the cytotoxic effect of SFN was investigated further. BSO, a specific inhibitor of γ-
GCS, was used to decrease GSH levels. The inhibition efficiency of BSO on the intracellular GSH level 
was characterized using HPLC (Supplementary Figure 3). BSO (50 µM) was used in the co-treatment 
with SFN as it showed 60-80% reduction in the GSH level and abolished the SFN-induced GSH rise. 
Nrf2 knockdown was achieved by siRNA transfection. The siRNA knockdown efficiency of Nrf2 was 
measured using Western blot analysis as previous described
45
. 
After 24 hours treatment with 50 µM BSO, the cell viability of HepG2 cells was still high at 
97.9% (Figure 4A). SFN treatment at 60 µM decreased HepG2 cell viability to 47.6%, which agreed 
with previous data; while co-treatment with BSO reduced the cell viability further to 25.7%. 
Furthermore, in control (Allstar transfected) cells, SFN (60 µM) decreased cell viability to 49.5% of 
control (0.1% DMSO); while in siNrf2 transfected cells, SFN decreased cell viability to 15.3% of 
controls. These data indicate clearly that reducing Nrf2 and GSH levels in HepG2 cells increased 
susceptibility to SFN toxicity. 
To investigate whether Nrf2 is the main gene responsible for the cytoprotective effect of 
SFN against H2O2-induced cell death in HepG2 cells, cells were transfected with siNrf2 (or Allstar as 
negative control), pre-treated with 5 µM SFN for 24 hours followed by H2O2 insult for another 24 
hours. Nrf2 knockdown enhanced the cytotoxicity of H2O2, i.e. cell viability was 47.6, 38.0 and 24.6% 
in the non-transfected, Allstar transfected and siNrf2 transfected cells respectively (Figure 4B). 5 µM 
SFN decreased the cytotoxicity of H2O2 in non-transfected and Allstar negative control cells, while 
the protective effect from SFN was abolished upon Nrf2 knockdown. The involvement of GSH in the 
SFN cytoprotective effect was also studied. Co-treatment with BSO and 5 µM SFN showed no 
protective effect against H2O2. Therefore, it can be concluded that the Nrf2/GSH signalling pathway 
plays an essential role in the protective effect of SFN against H2O2 challenges. 
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Figure 4. Effect of GSH inhibition and Nrf2 knockdown on SFN cytotoxic and cytoprotective effects in 
HepG2 cells. Allstars (AS) was used as a negative control. (A) Cells were incubated with 60 μM SFN or 
DMSO (0.1%) with or without BSO (50 μM) for 24 hours. (B) Cells were incubated with 5 μM SFN or 
DMSO (0.1%) with or without BSO (50 μM) for 24 hours, followed by exposure to 800 μM H2O2 for 
another 24 hours. Cell viability was measured by MTT assay, results represent the mean ± SD (n ≥ 5). 
Within each set of indicated columns, SFN treated groups were normalized against the mean of 
corresponding control groups. A student’s t-test was then performed to determine any statistical 
difference between two groups. **p <0.01 between the indicated groups. 
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Discussion 
The epidemiological evidence with respect to the consumption of dietary isothiocyanates as 
chemopreventive agents against cancer has been inconsistent. For example, results from a 
randomized, placebo-controlled trial in Qidong (China) indicated that intake of 400 µM 
glucoraphanin, the precursor of SFN, for 2 weeks altered the disposition of aflatoxin and 
phenanthrene in 200 healthy participants, both of which are known to contribute to the high risk of 
hepatocellular carcinoma in that region
46
. On the other hand, no association between urinary 
isothiocyantes exposure and liver cancer risk was found in a nested case-control study including 
Chinese men and women
47
. Consumption of cruciferous vegetables, at least one portion (around 
125g) per week, also showed no significant association with liver cancer risk reduction in data from 
case-control studies conducted in Italy and Switzerland
48
.  
An ideal chemopreventive agent should only have a minimal effect on normal cells but a 
strong inhibitory effect on cell proliferation and carcinogenic pathways in cancer cells. While there 
are many studies on both protective and cytotoxic effects of SFN, there is little data comparing its 
effect on normal cells with cancer cells. The study presented here is the first to compare the effects 
of SFN on immortalised hepatocytes (HHL5) versus the hepatoma cell line HepG2. 
SFN showed stronger cytotoxicity and genotoxicity in HHL5 than in HepG2. At 24 hours, 10 
µM SFN started to inhibit cell viability and induce DNA damage in HHL5 while in HepG2 only 
concentrations above 20 µM SFN had a significant cytotoxic and genotoxic effect. Since the cytotoxic 
effects of SFN and H2O2 have been linked to the disruption of the redox status of the cells
49,50
, the 
different sensitivities towards oxidative stress between these two cell lines observed is possibly due 
to differences in their Nrf2-driven enzymes and GSH response systems. Indeed, results showed that 
HepG2 cells had higher basal levels of intracellular GSH, nuclear Nrf2 and some of the phase II 
enzyme such as CAT, HO-1, NQO1, than HHL5 cells, which could indicate they have an enhanced 
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defence system against ROS compared to HHL5 cells. Targeting tumor detoxification enzymes has 
been considered as an attractive strategy for selective antitumor therapy
51–53
. 
More interestingly, SFN increased nuclear Nrf2 levels and intracellular GSH levels in both cell 
lines but with slightly different patterns. Short term SFN exposure (3-6 hours) of HHL5 cells depleted 
intracellular GSH for longer and exhibited lower induction of Nrf2 nuclear accumulation compared to 
HepG2 cells. These findings indicate that SFN may exhibit strong pro-survival effects in HepG2 cells, 
which is in line with the results shown in Figure 2. Pre-treatment for 24 hours with SFN provided 
protection against H2O2-induced cell injury in both cell lines. However, in HHL5 cells, SFN at high 
doses (10-20 µM) failed to show a protective effect against H2O2-induced cell death and DNA 
damage. 
Nrf2 is generally considered as a primary defence mechanism of the cell and a major 
regulator of cell survival. Nrf2 deficient mice are more susceptible to carcinogenesis
54,55
. Many have 
reported the chemopreventive effect of Nrf2 in cancer
56–58
. However, the results of the present 
study indicate that in HepG2, the inhibition of Nrf2/GSH increased SFN cytotoxicity and decreased its 
cytoprotective effect against H2O2 challenge, i.e., both Nrf2 and GSH substantially contributed to the 
preservation of cell integrity under conditions of SFN and H2O2 treatment in HepG2 cells. The 
knockdown of Nrf2 increased cell death even further in both cell lines compared to GSH inhibition, 
indicating that more Nrf2 targets might be involved. Essentially, Nrf2 protects not only normal cells 
but also transforming/cancer cells. With increasing evidence suggesting that Nrf2 is upregulated in 
cancer cells or resistance strains
59,60
, and that it contributes to the aggressive cancer phenotype
61
, it 
has become more important to rationalise the usage of Nrf2 inhibitors vs activators. In this study, 
HepG2 cells were able to take advantage of the SFN-induced protective effects, and better resist 
SFN-induced disruptions than HHL5 cells, indicating a potential risk of chemo-resistance of using SFN 
for chemoprevention. More rigorous dose-response comparisons of efficacy versus toxicity need to 
be performed in vivo with consideration of the differences between normal and cancer cells. 
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In conclusion, human hepatoma HepG2 cells were more resistant to SFN exposure compared 
to immortalised heptocyte HHL5 cells, which may be due to their intrinsic high expression of 
Nrf2/GSH. SFN exhibited strong cytoprotective effects due to the activation of Nrf2 and the 
induction of GSH in both cell lines. Although in vitro studies do not necessarily predict in vivo 
outcomes, these findings raise the question that SFN may induce pro-survival effects in cancer cells. 
Therefore, a combination of inhibition Nrf2/GSH and chemopreventive agents may be a better 
strategy in cancer management since multiple targeted approaches can improve the efficacy of anti-
cancer drugs and minimise the adverse effects toward normal cells.  
 
Acknowledgements: The authors wish to thank Chris Washbourne for help in using the HPLC 
facilities, Dr Andrew Smith, Professor Michael Wormstone and Human Research Trust for setting up 
the Comet assay, Dr A. Patel, Medical Research Council (MRC) Virology Unit (Glasgow, UK) for 
supplied the HHL-5 cells. We also thank Mr Jim Bacon for helpful discussion during the preparation 
of this manuscript.  
 
Financial Support: This work was supported by an International PhD Studentship (UEA) to P. Liu, and 
in part, an award from the Cancer Prevention Research Trust (UK) to Y. Bao. We also would like to 
thank The Humane Research Trust and the John and Pamela Salter Charitable Trust for their support 
of the equipment and software for the Comet Assay. 
 
Conflicts of Interest:  
None. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
References 
1. Zhang, Y., Talalay, P., Cho, C. G. & Posner, G. H. A major inducer of anticarcinogenic 
protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl. Acad. Sci. 
U. S. A. 89, 2399–2403 (1992). 
2. Nakagawa, K. et al. Evaporative light-scattering analysis of sulforaphane in broccoli samples: 
Quality of broccoli products regarding sulforaphane contents. J. Agric. Food Chem. 54, 2479–
2483 (2006). 
3. Baird, L. & Dinkova-Kostova, A. T. The cytoprotective role of the Keap1-Nrf2 pathway. 
Archives of Toxicology 85, 241–272 (2011). 
4. Zhang, D. D. et al. Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, 
targets Keap1 for degradation by a proteasome-independent pathway. J. Biol. Chem. 280, 
30091–30099 (2005). 
5. Katoh, Y. et al. Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-
mediated degradation of the protein by proteasome. Arch. Biochem. Biophys. 433, 342–350 
(2005). 
6. Hu, C., Eggler, A. L., Mesecar, A. D. & Van Breemen, R. B. Modification of Keap1 cysteine 
residues by sulforaphane. Chem. Res. Toxicol. 24, 515–521 (2011). 
7. Townsend, D. M., Tew, K. D. & Tapiero, H. The importance of glutathione in human disease. 
Biomedicine and Pharmacotherapy 57, 145–155 (2003). 
8. Lu, S. C. Regulation of glutathione synthesis. Molecular Aspects of Medicine 30, 42–59 (2009). 
9. Thimmulappa, R. K. et al. Identification of Nrf2-regulated genes induced by the 
chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 62, 5196–
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
22 
 
5203 (2002). 
10. Mitsuishi, Y. et al. Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic 
Reprogramming. Cancer Cell 22, 66–79 (2012). 
11. Moon, D. O. et al. Sulforaphane decreases viability and telomerase activity in hepatocellular 
carcinoma Hep3B cells through the reactive oxygen species-dependent pathway. Cancer Lett. 
295, 260–266 (2010). 
12. Liu, H. et al. Sulforaphane promotes ER stress, autophagy, and cell death: implications for 
cataract surgery. J. Mol. Med. 95, 553–564 (2017). 
13. Chung, Y. K. et al. Sulforaphane down-regulates SKP2 to stabilize p27
KIP1
 for inducing 
antiproliferation in human colon adenocarcinoma cells. J. Biosci. Bioeng. 119, 35–42 (2015). 
14. Tang, L. & Zhang, Y. Mitochondria are the primary target in isothiocyanate-induced apoptosis 
in human bladder cancer cells. Mol. Cancer Ther. 4, 1250–1259 (2005). 
15. Jackson, S. J. T. & Singletary, K. W. Sulforaphane: A naturally occuring mammary carcinoma 
mitotic inhibitor, which disrupts tubulin polymerization. Carcinogenesis 25, 219–227 (2004). 
16. Jackson, S. J. T., Singletary, K. W. & Venema, R. C. Sulforaphane suppresses angiogenesis and 
disrupts endothelial mitotic progression and microtubule polymerization. Vascul. Pharmacol. 
46, 77–84 (2007). 
17. Byun, S. et al. Sulforaphene suppresses growth of colon cancer-derived tumors via induction 
of glutathione depletion and microtubule depolymerization. Mol. Nutr. Food Res. 60, 1068–
1078 (2016). 
18. Sestili, P. et al. Sulforaphane induces DNA single strand breaks in cultured human cells. Mutat. 
Res. 689, 65–73 (2010). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
23 
 
19. Pham, N. A. et al. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell 
cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth 
in severe combined immunodeficient mice. Mol Cancer Ther 3, 1239–1248 (2004). 
20. Gamet-Payrastre, L. et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell 
cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 60, 1426–1433 
(2000). 
21. Suppipat, K., Park, C. S., Shen, Y., Zhu, X. & Lacorazza, H. D. Sulforaphane Induces Cell Cycle 
Arrest and Apoptosis in Acute Lymphoblastic Leukemia Cells. PLoS One 7, (2012). 
22. Park, H. S. et al. Sulforaphane induces reactive oxygen species-mediated mitotic arrest and 
subsequent apoptosis in human bladder cancer 5637 cells. Food Chem. Toxicol. 64, 157–165 
(2014). 
23. Herz, C. et al. The isothiocyanate erucin abrogates telomerase in hepatocellular carcinoma 
cells in vitro and in an orthotopic xenograft tumour model of HCC. J. Cell. Mol. Med. 18, 
2393–2403 (2014). 
24. Li, Y. et al. Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50Cdc37 
complex and direct interactions with amino acids residues of Hsp90. J. Nutr. Biochem. 23, 
1617–1626 (2012). 
25. Pledgie-Tracy, A., Sobolewski, M. D. & Davidson, N. E. Sulforaphane induces cell type-specific 
apoptosis in human breast cancer cell lines. Mol. Cancer Ther. 6, 1013–1021 (2007). 
26. Clarke, J. D., Hsu, A., Yu, Z., Dashwood, R. H. & Ho, E. Differential effects of sulforaphane on 
histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus 
hyperplastic and cancerous prostate cells. Mol. Nutr. Food Res. 55, 999–1009 (2011). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
24 
 
27. Zeng, H., Trujillo, O.N., Moyer, M.P., Botnen, J. H. Prolonged sulforaphane treatment 
activates survival signaling in nontumorigenic NCM460 colon cells but apoptotic signaling in 
tumorigenic HCT116 colon cells. Nutr. Cancer 15, 2379–2381 (2013). 
28. Beaver, L.M. et al. Transcriptome analysis reveals a dynamic and differential transcriptional 
response to sulforaphane in normal and prostate cancer cells and suggests a role for Sp1 in 
chemoprevention. Molecular Nutrition and Food Research 58, 2001–2013 (2014). 
29. Misiewicz, I., Skupinska, K. & Kasprzycka-Guttman, T. Differential response of human healthy 
lymphoblastoid and CCRF-SB leukemia cells to sulforaphane and its two analogues: 2-
oxohexyl isothiocyanate and alyssin. Pharmacol. Reports 59, 80–87 (2007). 
30. Fimognari, C. et al. Isothiocyanates as novel cytotoxic and cytostatic agents: Molecular 
pathway on human transformed and non-transformed cells. in Biochemical Pharmacology 68, 
1133–1138 (2004). 
31. Wong, C. P. et al. Effects of sulforaphane and 3,3′-diindolylmethane on genome-wide 
promoter methylation in normal prostate epithelial cells and prostate cancer cells. PLoS One 
9, (2014). 
32. Lubelska, K. et al. Sulforaphane Regulates NFE2L2/Nrf2-Dependent Xenobiotic Metabolism 
Phase II and Phase III Enzymes Differently in Human Colorectal Cancer and Untransformed 
Epithelial Colon Cells. Nutr. Cancer 68, 1338–1348 (2016). 
33. Wang, Y. et al. Synergy between sulforaphane and selenium in protection against oxidative 
damage in colonic CCD841 cells. Nutr. Res. (2015). 
34. Negrette-Guzman, M. et al. Sulforaphane induces differential modulation of mitochondrial 
biogenesis and dynamics in normal cells and tumor cells. Food Chem. Toxicol. 100, 90–102 
(2017). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
25 
 
35. Constantinescu, S. et al. Transcriptomic responses of cancerous and noncancerous human 
colon cells to sulforaphane and selenium. Chem. Res. Toxicol. 27, 377–386 (2014). 
36. Agyeman, A. S. et al. Transcriptomic and proteomic profiling of KEAP1 disrupted and 
sulforaphane-treated human breast epithelial cells reveals common expression profiles. 
Breast Cancer Res. Treat. 132, 175–187 (2012). 
37. Clayton, R. F. et al. Liver cell lines for the study of hepatocyte functions and immunological 
response. Liver Int. 25, 389–402 (2005). 
38. Liu, P. et al. Chemopreventive Activities of Sulforaphane and Its Metabolites in Human 
Hepatoma HepG2 Cells. Nutrients 10, 585 (2018). 
39. Wang, W. et al. Sulforaphane protects the liver against CdSe quantum dot-induced 
cytotoxicity. PLoS One 10, (2015). 
40. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image 
analysis. Nat. Methods 9, 671–675 (2012). 
41. Charames, G. S. & Bapat, B. Genomic instability and cancer. J. Mol. Cell Biol. 3, 1–3 (2003). 
42. Hirao, A. et al. DNA Damage-Induced Activation of p53 by the Checkpoint Kinase Chk2. 
Science (80-. ). 287, 1824–1827 (2000). 
43. Kim, B. R. et al. Effects of Glutathione on Antioxidant Response Element-Mediated Gene 
Expression and Apoptosis Elicited by Sulforaphane. Cancer Res. 63, 7520–7525 (2003). 
44. Li, D. et al. Synergy between sulforaphane and selenium in the up-regulation of thioredoxin 
reductase and protection against hydrogen peroxide-induced cell death in human 
hepatocytes. Food Chem. 133, 300–307 (2012). 
45. Liu, P. et al. Anti-cancer activities of allyl isothiocyanate and its conjugated silicon quantum 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
26 
 
dots. Sci. Rep. 8, (2018). 
46. Kensler, T. W. et al. Effects of glucosinolate-rich broccoli sprouts on urinary levels of 
aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo 
Township, Qidong, People’s Republic of China. Cancer Epidemiol. Biomarkers Prev. 14, 2605–
2613 (2005). 
47. Wu, Q. J. et al. Urinary isothiocyanates level and liver cancer risk: a nested case-control study  
in Shanghai, China. Nutr. Cancer 66, 1023–1029 (2014). 
48. Bosetti, C. et al. Cruciferous vegetables and cancer risk in a network of case-control studies. 
Ann. Oncol. 23, 2198–2203 (2012). 
49. Sestili, P. & Fimognari, C. Cytotoxic and Antitumor Activity of Sulforaphane: The Role of 
Reactive Oxygen Species. Biomed Res. Int. 2015, 1–9 (2015). 
50. Sies, H. Role of metabolic H2O2 generation: Redox signaling and oxidative stress. Journal of 
Biological Chemistry 289, 8735–8741 (2014). 
51. Bauer, G. Tumor cell-protective catalase as a novel target for rational therapeutic approaches 
based on specific intercellular ROS signaling. Anticancer Research 32, 2599–2624 (2012). 
52. Oh, E. T. & Park, H. J. Implications of NQO1 in cancer therapy. BMB Reports 48, 609–617 
(2015). 
53. Chau, L. Y. Heme oxygenase-1: Emerging target of cancer therapy. Journal of Biomedical 
Science 22, (2015). 
54. Yokoo, Y. et al. Effects of Nrf2 silencing on oxidative stress-associated intestinal 
carcinogenesis in mice. Cancer Med. 5, 1228–1238 (2016). 
55. Cheung, K. L. et al. Nrf2 knockout enhances intestinal tumorigenesis in Apcmin/+ mice due to 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
27 
 
attenuation of anti-oxidative stress pathway while potentiates inflammation. Mol. Carcinog. 
53, 77–84 (2014). 
56. Lu, M. C., Ji, J. A., Jiang, Z. Y. & You, Q. D. The Keap1–Nrf2–ARE Pathway As a Potential 
Preventive and Therapeutic Target: An Update. Medicinal Research Reviews 36, 924–963 
(2016). 
57. Russo, M. et al. Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment. Crit. 
Rev. Food Sci. Nutr. 58, 1391–1405 (2018). 
58. Krajka-Kuźniak, V., Paluszczak, J. & Baer-Dubowska, W. The Nrf2-ARE signaling pathway: An 
update on its regulation and possible role in cancer prevention and treatment. 
Pharmacological Reports 69, 393–402 (2017). 
59. Taguchi, K., Motohashi, H. & Yamamoto, M. Molecular mechanisms of the Keap1-Nrf2 
pathway in stress response and cancer evolution. Genes to Cells 16, 123–140 (2011). 
60. Menegon, S., Columbano, A. & Giordano, S. The Dual Roles of NRF2 in Cancer. Trends in 
Molecular Medicine 22, 578–593 (2016). 
61. Kansanen, E., Kuosmanen, S. M., Leinonen, H. & Levonenn, A. L. The Keap1-Nrf2 pathway: 
Mechanisms of activation and dysregulation in cancer. Redox Biol. 1, 45–49 (2013). 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Highlights  
 
Please amend your research highlights so that they consist of 3 to 5 brief bullet points which convey 
the core findings of your work. Please ensure EACH bullet point does NOT exceed 125 characters 
(including spaces). An example is given below: 
RESEARCH HIGHLIGHTS EXAMPLE: 
* Research highlights are a mandatory field of a submitted paper & therefore should not exceed 85 
characters including spaces. 
 
* Sulforaphane exhibited biphasic effects on cell viability and DNA integrity in both cancer and 
normal cells  
* Nrf2/GSH system was involved in the protective effects of sulforaphane against oxidative stress at 
low dose 
* Cancer cells showed higher basal level of detoxification enzymes such as CAT, HO-1 and NQO1 
compared to normal cells  
* Cancer cells hijacked the cytoprotective effect of sulforaphane over a wider dose range compared 
to normal cells 
* The adverse effect of anti-cancer drugs (phytochemicals) might be under-estimated using cancer 
cell lines 
 
 
 
